XML 42 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1

Summary of Significant Accounting Policies - Collaborative Research and Licensing Agreements - Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue recognition
Total	$ 4,448,000								$ 4,448,000
Revenue recognized	10,941	$ 7,090	$ 13,340	$ 4,340	$ 6,440	$ 7,821	$ 66,007	$ 7,252	35,711	$ 87,520	$ 27,762
Deferred revenue	94,400				$ 103,400				94,400	103,400
Development-based
Revenue recognition
Total	827,000								827,000
Regulatory-based
Revenue recognition
Total	1,490,000								1,490,000
Sales-based
Revenue recognition
Total	2,131,000								2,131,000
UNITED STATES
Revenue recognition
Revenue recognized									19,700	84,800	22,400
Non United States
Revenue recognition
Revenue recognized									16,000	2,700	5,400
Alexion Pharmaceuticals, Inc.
Revenue recognition
Total	58,000								58,000
Revenue recognized									1,000	6,000	8,500
Alexion Pharmaceuticals, Inc. | Regulatory-based
Revenue recognition
Total	28,000								28,000
Alexion Pharmaceuticals, Inc. | Sales-based
Revenue recognition
Total	30,000								30,000
Amgen, Inc.
Revenue recognition
Total	1,647,500								1,647,500
Revenue recognized									16,200	18,700	13,800
Amgen, Inc. | Development-based
Revenue recognition
Total	222,500								222,500
Amgen, Inc. | Regulatory-based
Revenue recognition
Total	345,000								345,000
Amgen, Inc. | Sales-based
Revenue recognition
Total	1,080,000								1,080,000
BI
Revenue recognition
Total	27,000								27,000
BI | Development-based
Revenue recognition
Total	9,000								9,000
BI | Regulatory-based
Revenue recognition
Total	6,000								6,000
BI | Sales-based
Revenue recognition
Total	12,000								12,000
CSL Limited
Revenue recognition
Revenue recognized									3,500		2,500
Janssen
Revenue recognition
Total	10,000								10,000
Janssen | Development-based
Revenue recognition
Total	6,000								6,000
Janssen | Sales-based
Revenue recognition
Total	4,000								4,000
MorphoSys
Revenue recognition
Total	286,500								286,500
Revenue recognized									12,500
MorphoSys | Development-based
Revenue recognition
Total	49,500								49,500
MorphoSys | Regulatory-based
Revenue recognition
Total	187,000								187,000
MorphoSys | Sales-based
Revenue recognition
Total	50,000								50,000
Novo Nordisk
Revenue recognition
Revenue recognized										2,700	2,900
Novartis
Revenue recognition
Total	2,410,000								2,410,000
Revenue recognized									2,300	59,700
Novartis | Development-based
Revenue recognition
Total	540,000								540,000
Novartis | Regulatory-based
Revenue recognition
Total	920,000								920,000
Novartis | Sales-based
Revenue recognition
Total	950,000								950,000
Other
Revenue recognition
Revenue recognized									200	400	100
2009 Research License and Commercialization Agreement | CSL Limited
Revenue recognition
Total	9,000								9,000
Revenue recognized									3,500	$ 0	$ 2,500
Deferred revenue	0								0
2009 Research License and Commercialization Agreement | CSL Limited | Regulatory-based
Revenue recognition
Total	4,000								4,000
2009 Research License and Commercialization Agreement | CSL Limited | Sales-based
Revenue recognition
Total	$ 5,000								$ 5,000

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the revenue earned during the period pertaining to collaborations, licenses and milestones.

+ References

No definition available.

+ Details

Name:	xncr_CollaborationsLicensesAndMilestonesRevenue
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties.

+ References

No definition available.

+ Details

Name:	xncr_RevenueRecognitionMilestoneMethodPending
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	xncr_PotentialMilestonesTypeAxis=xncr_DevelopmentBasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_PotentialMilestonesTypeAxis=xncr_RegulatoryBasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_PotentialMilestonesTypeAxis=xncr_SalesBasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=xncr_NonUnitedStatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_AmgenIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_BIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_CSLLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_JanssenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_MorphoSysMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_NovoNordiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_NovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_OtherCustomerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xncr_ResearchLicenseAndCommercialization2009AgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: